Drug Trial Radar · NCT00567567
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Last checked: Nov 19, 2026Latest source record: Apr 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
665
Actual
Start
Nov 5, 2007
Primary completion
Feb 27, 2015
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Dec 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial compares two different high-dose chemotherapy regimens followed by a stem cell transplant in treating younger patients with high-risk neuroblastoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments before a peripheral blood stem cell transplant helps kill any tumor cells that are in the body and helps make room in the patient?s bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. High-dose chemotherapy and radiation therapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the high- chemotherapy. It is not yet known which regimen of high-dose chemotherapy is more effective for patients with high-risk neuroblastoma undergoing a peripheral blood stem cell transplant.
Conditions
- Localized Resectable Neuroblastoma
- Localized Unresectable Neuroblastoma
- Recurrent Neuroblastoma
- Regional Neuroblastoma
- Stage 4 Neuroblastoma
- Stage 4S Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell TransplantationProcedure
Undergo autologous peripheral blood stem cell transplant
CarboplatinDrug
Given IV
CisplatinDrug
Given IV
CyclophosphamideDrug
Given IV
Doxorubicin HydrochlorideDrug
Given IV
EtoposideDrug
Given IV
External Beam Radiation TherapyRadiation
Undergo EBRT
FilgrastimBiological
Given IV or SC
IsotretinoinDrug
Given orally
Laboratory Biomarker AnalysisOther
Correlative studies
MelphalanDrug
Given IV
Peripheral Blood Stem Cell TransplantationProcedure
Undergo autologous peripheral blood stem cell transplant
Pharmacological StudyOther
Correlative studies
ThiotepaDrug
Given IV
Topotecan HydrochlorideDrug
Given IV
Vincristine Sulfate LiposomeDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free Survival RateTime frame: Three years, from time of randomization
- Response After Induction TherapyTime frame: Study enrollment to the end of induction therapy
- Incidence Rate of Local RecurrenceTime frame: Up to 3 years
Locations
190 sites in 6 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
USA Health Strada Patient Care Center
Mobile, Alabama
Phoenix Childrens Hospital
Phoenix, Arizona
The University of Arizona Medical Center-University Campus
Tucson, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente Downey Medical Center
Downey, California
City of Hope Comprehensive Cancer Center
Duarte, California
Loma Linda University Medical Center
Loma Linda, California
Miller Children's and Women's Hospital Long Beach
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
Cedars Sinai Medical Center
Los Angeles, California
Valley Children's Hospital
Madera, California
Children's Hospital and Research Center at Oakland
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
Lucile Packard Children's Hospital Stanford University
Palo Alto, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Rady Children's Hospital - San Diego
San Diego, California
UCSF Medical Center-Mount Zion
San Francisco, California
UCSF Medical Center-Parnassus
San Francisco, California
Harbor-University of California at Los Angeles Medical Center
Torrance, California
Children's Hospital Colorado
Aurora, Colorado
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado
University of Connecticut
Farmington, Connecticut
Connecticut Children's Medical Center
Hartford, Connecticut
Alfred I duPont Hospital for Children
Wilmington, Delaware
Children's National Medical Center
Washington D.C., District of Columbia
Broward Health Medical Center
Fort Lauderdale, Florida
Lee Memorial Health System
Fort Myers, Florida
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida
University of Florida Health Science Center - Gainesville
Gainesville, Florida
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida
Nicklaus Children's Hospital
Miami, Florida
Florida Hospital Orlando
Orlando, Florida
Nemours Children's Clinic - Orlando
Orlando, Florida
UF Cancer Center at Orlando Health
Orlando, Florida
Showing 40 of 190 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.